Clinical Trials Logo

Filter by:
NCT ID: NCT05043922 Recruiting - Ovarian Cancer Clinical Trials

A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma

Start date: August 13, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the treatment efficacy of CYH33 monotherapy in patients with recurrent or persistent ovarian, fallopian tube or primary peritoneal clear cell carcinoma harboring PIK3CA hotspot mutation, who received prior systemic anti-tumor treatment.

NCT ID: NCT05043870 Recruiting - Crohn Disease Clinical Trials

Combined Immunosuppression for Pediatric Crohn's Disease

Start date: October 10, 2022
Phase: Phase 4
Study type: Interventional

This is a randomized controlled trial to compare the efficacy and safety of infliximab and immunosuppressives therapy alone or in combination for pediatric Crohn's disease.

NCT ID: NCT05043675 Recruiting - Alzheimer Disease Clinical Trials

Clinical Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients

Start date: September 10, 2021
Phase: Early Phase 1
Study type: Interventional

The overall objective of this study is to evaluate the overall pattern of [18F]APN-1607 uptake in subjects with AD dementia

NCT ID: NCT05043662 Recruiting - Clinical trials for Urothelial Carcinoma

UroCAD Assay Combined With Computed Tomography Urography and Urine Cytology for UTUC Diagnosis.

Start date: September 1, 2021
Phase:
Study type: Observational

Upper tract urothelial carcinoma (UTUC) diagnosis include urography using computed tomography urography (CTU) or urography using MRI (MRU). The sensitivity of CTU decreases substan¬tially with decreasing lesion size. Other drawbacks of CTU include the radiation exposure and potential adverse effects in patients with allergic reactions or pre-existing renal impairment. In terms of urine cytology, the major drawbacks of urine cytology are low sensitivity and highly dependent of the experience and skills of the cytopathologist. We here intended to investigate whether UroCAD can be added in the diagnostic work-up of UTUC patient, and improve the accuracy of predicting UTUC before surgery.

NCT ID: NCT05043298 Recruiting - Clinical trials for Advanced Solid Tumor

A Phase Ia/Ib Clinical Trial of IBI360 Monotherapy or in Combination With Sintilimab and (or) Chemotherapy in Advanced or Metastatic Solid Tumors

Start date: October 27, 2021
Phase: Phase 1
Study type: Interventional

This is an open label Phase Ia/Ib trial to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of IBI360 monotherapy in Advanced or Metastatic Solid Tumors

NCT ID: NCT05043272 Recruiting - Covid19 Clinical Trials

Safety and Immune Response of COVID-19 Vaccination in Overweight People With Excessive BMI

Start date: August 1, 2021
Phase:
Study type: Observational

On 11 February 2020, the International Committee for the Classification of Viruses named the disease caused by SARS-CoV-2 infection in humans as the new coronavirus pneumonia (coronavirus disease 2019, COVID-19). Due to the changes of immune function and cardiopulmonary function in overweight people, the infection and severity of these patients are higher than that of the general population during the epidemic period. More attention should be paid to personal protection and disease prevention. Vaccination with COVID-19 vaccine can effectively prevent COVID-19 infection, delay or prevent patients from developing into critical illness and reducing mortality. In order to evaluate the safety and efficacy of COVID-19 vaccine for overweight people, and to guide COVID-19 vaccination more scientifically, rationally and effectively, this study was carried out.

NCT ID: NCT05043246 Recruiting - Covid19 Clinical Trials

Safety and Immune Response of COVID-19 Vaccination in Patients With Basic Disease

SIM-PBD
Start date: August 1, 2021
Phase:
Study type: Observational

On 11 February 2020, the International Committee for the Classification of Viruses named the disease caused by SARS-CoV-2 infection in humans as the new coronavirus pneumonia (coronavirus disease 2019, COVID-19).Due to the decline of immunity and cardiopulmonary function in patients with basic diseases (hypertension, diabetes, chronic obstructive pulmonary disease, chronic kidney disease, cancer diseases, etc.), COVID-19 's severe illness and mortality mainly increase in these special population. Vaccination of COVID-19 vaccine can effectively prevent COVID-19 virus infection and delay or prevent patients from developing into critical illness and reduce mortality.To evaluate the safety and effectiveness of the population vaccinated with COVID-19 vaccine, and to play a scientific and theoretical supporting role in guiding COVID-19 vaccination scientifically, reasonably and effectively, so this study was carried out.

NCT ID: NCT05043233 Recruiting - Clinical trials for Patient Acceptance of Health Care

Observation in the Treatment of Graves' Disease

Start date: October 1, 2020
Phase:
Study type: Observational [Patient Registry]

At present, there are still few observational studies on Graves' disease in China, and there are few research reports in this regard. In order to further carry out high-quality observational follow-up research on Graves' disease hyperthyroidism, including establishing standard diagnosis and treatment procedures, providing data support for the establishment of research protocols such as sample size and follow-up time estimation, this study was conducted at Ruijin Hospital, Shanghai Jiaotong University School of Medicine. The endocrinology clinic carried out the registration follow-up study of Graves' disease.

NCT ID: NCT05043194 Recruiting - Clinical trials for Cholestasis of Parenteral Nutrition

Ursodeoxycholic Acid Prevents Total Parenteral Nutrition Cholestasis

UDACPPNAC
Start date: January 1, 2021
Phase: N/A
Study type: Interventional

This study aims to confirm whether the preventive use of ursodeoxycholic acid on the 5th day after birth in preterm infants who started parenteral nutrition therapy can reduce the occurrence of enteral nutrition-related cholestasis in preterm infants. This study examined the safety and efficacy of ursodeoxycholic acid (UDCA) in preventing Cholestasis Associated with Total Parenteral Nutrition in preterm infants.

NCT ID: NCT05043129 Recruiting - HIV Infections Clinical Trials

Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection

Start date: September 4, 2021
Phase:
Study type: Observational

On 11 February 2020, the International Committee for the Classification of Viruses named the disease caused by SARS-CoV-2 infection in humans as the new coronavirus pneumonia (coronavirus disease 2019, COVID-19). People infected with human immunodeficiency virus (HIV) are affected by their underlying diseases and are listed by the World Health Organization (WHO) as a high-risk population of SARS-CoV-2 infection.To evaluate the safety and effectiveness of COVID-19 vaccine in those patients with human immunodeficiency virus infection , and to guide the COVID-19 vaccination more scientifically, reasonably and effectively, this study was carried out.